Official List Suspension - Roquefort Therapeutics plc (0620Y)

TIDMROQ

RNS Number : 0620Y

Official List

02 May 2023

 
 NOTICE OF TEMPORARY SUSPENSION OF LISTING FROM THE OFFICIAL LIST 
 02/05/2023 07:30 
 TEMPORARY SUSPENSION 
 Roquefort Therapeutics plc 
 The Financial Conduct Authority ("the FCA") temporarily suspends the securities set out below 
  from the Official List effective from 02/05/2023 07:30 at the request of the company: 
 
 
  Security Description           Listing Category    ISIN 
   Ordinary shares of 1p each;    Standard Shares     GB00BMDQ2T15 
    fully paid                                         -- 
                                ==================  ============== 
 This notice has been issued by Issuer Management - 020 7066 8352. Notes 
 
  SEDOL numbers which are allocated by the London Stock Exchange as a Stock Exchange 
  identifier 
  may be found on their dealing notice. 
 
  --Denotes the security is being admitted to trading on the London Stock Exchange, a 
  Recognised 
  Investment Exchange. 
 
  Denotes the security is also being admitted to trading on Aquis Stock Exchange, a 
  Recognised 
  Investment Exchange. 
 
  #Denotes the security is also being admitted to trading on Euronext, a Recognised 
  Investment 
  Exchange. 
 
  Denotes the security is also being admitted to trading on Cboe Europe, a Recognised 
  Investment 
  Exchange. 
 
  ^Denotes the security is also being admitted to trading on Shanghai-London Stock 
  Connect, 
  a Recognised Investment Exchange. 
 
  *Denotes the security is also being admitted to trading on IPSX Prime, a Recognised 
  Investment 
  Exchange. 
 
  Notices issued by the FCA in respect of admission of securities to the Official List 
  must 
  be read in conjunction with notices issued by the relevant Recognised Investment 
  Exchange 
  in respect of admission of securities to trading on its markets. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

SUSNKBBKABKKCPK

(END) Dow Jones Newswires

May 02, 2023 02:30 ET (06:30 GMT)